Azole resistance in Candida albicans.
An isolate of Candida albicans from a patient with chronic mucocutaneous candidosis who relapsed during ketoconazole treatment was compared with a number of other azole-sensitive and azole-resistant isolates by tests in vitro and in three animal models of vaginal or disseminated infection. In-vitro tests indicated that the isolate was cross-resistant to all imidazole and triazole antifungals tested. In the animal models, treatment with miconazole, ketoconazole, itraconazole or fluconazole failed to influence the infection.
D000328:Adult; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002176:Candida albicans / Q000187:drug effects*; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D002178:Candidiasis, Chronic Mucocutaneous / Q000188:drug therapy* / Q000382:microbiology; D004195:Disease Models, Animal; D004352:Drug Resistance, Microbial; D004464:Econazole / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D015725:Fluconazole; D006168:Guinea Pigs; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D017964:Itraconazole; D007654:Ketoconazole / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008825:Miconazole / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D011919:Rats, Inbred Strains; D014230:Triazoles / Q000494:pharmacology* / Q000627:therapeutic use
D000935:Antifungal Agents; D007093:Imidazoles; D014230:Triazoles; C037815:terconazole; D017964:Itraconazole; D004464:Econazole; D008825:Miconazole; D015725:Fluconazole; D007654:Ketoconazole